OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Yacoub on Efficacy and Safety Results With Parsaclisib in Myelofibrosis

May 6th 2021

Abdulraheem Yacoub, MD, discusses efficacy and safety results with parsaclisib in myelofibrosis.

Dr. Goy on the Durability of Response With Brexucabtagene Autoleucel in MCL

May 6th 2021

Andre H. Goy, MD, discusses the durability of response with brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Marshall on Early Data With Trastuzumab Deruxtecan in HER2+ CRC

May 6th 2021

John L. Marshall, MD, discusses early data reported with fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive colorectal cancer from the phase 2 DESTINY-CRC01 trial.

Dr. Uboha on Early Efficacy Data With Zanidatamab in HER2+ Upper GI Cancers

May 5th 2021

Nataliya V. Uboha, MD, PhD, discusses early efficacy data demonstrated with zanidatamab in HER2-expressing upper gastrointestinal cancers.

Dr. Grothey on the Potential Role of ctDNA in Screening for CRC

May 5th 2021

Axel Grothey, MD, discusses the potential role of circulating tumor DNA testing in screening patients for early-stage colorectal cancer.

Dr. Davies on the Potential Utility of ERK Inhibitors in Melanoma

May 5th 2021

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

Dr. Alkharabsheh on Future Research Directions in MPNs

May 5th 2021

Omar Alkharabsheh, MD, discusses future research directions for the treatment of patients with myeloproliferative neoplasms.

Dr. Shafique on Selecting Between Selpercatinib and Pralsetinib in RET+ NSCLC

May 4th 2021

Michael Shafique, MD, discusses treatment considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Dr. Gorlick on the Challenges of Identifying Immunotherapeutic Targets in Osteosarcomas

May 4th 2021

Richard Gorlick, MD, discusses the challenges of identifying immunotherapeutic targets in osteosarcomas.

Dr. Rapisuwon on the Potential Utility of Toripalimab in Melanoma Subtypes

May 4th 2021

Suthee Rapisuwon, MD, discusses the potential utility of toripalimab in melanoma subtypes.

Dr. D’Angelo on Selecting CAR T-Cell Therapy or Transplantation in DLBCL

May 4th 2021

Christopher R. D’Angelo, MD, discusses factors that determine whether CAR T-cell therapy or autologous stem cell transplant should be used in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Verstovsek on the Efficacy of Ruxolitinib Plus CPI-0610 in Myelofibrosis

May 3rd 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy of ruxolitinib in combination with CPI-0610 in myelofibrosis.

Dr. Barrientos on Selecting Between BCL-2 Inhibitors and BTK Inhibitors in CLL

May 3rd 2021

Jacqueline Claudia Barrientos, MD, MS, discusses factors to consider when selecting between BCL-2 inhibitors and BTK inhibitors in chronic lymphocytic leukemia.

Dr. Maura on the Challenges of Whole-Genome Sequencing in Multiple Myeloma

May 3rd 2021

Francesco Maura, MD, discusses the challenges of whole-genome sequencing in multiple myeloma.

Dr. Hahn on the Impact of Trastuzumab Emtansine in HER2+ Breast Cancer

May 3rd 2021

Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.

Dr. Kim on the FDA Approval of TheraSphere Y-90 Glass Microspheres in HCC

April 30th 2021

Edward Kim, MD, discusses the FDA approval of TheraSphere™ Yttrium-90 Glass Microspheres in hepatocellular carcinoma.

Dr. Hahn on the Convenience of Subcutaneous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

April 30th 2021

Olwen Hahn, MD, discusses the convenience of the fixed-dose combination of trastuzumab and pertuzumab in a subcutaneous formulation in HER2-positive breast cancer.

Dr. Saltos on the Importance of Broad Molecular Testing in NSCLC

April 30th 2021

Andreas Saltos, MD, discusses the importance of broad molecular testing in non–small cell lung cancer.

Dr. Radich on the Impact of MRD on Survival Outcomes in AML

April 30th 2021

Jerald Radich, MD, discusses the impact of minimal residual disease on survival outcomes in patients with acute myeloid leukemia.

Dr. Fleury on the Advancement of Decentralized Clinical Trials During COVID-19

April 29th 2021

Mark Fleury, PhD, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.